China Medical System will pay Insilico Medicine up to $177 million in milestone payments for a research and development program in the central nervous system disease field.
The collaboration targets a mass-market indication in central nervous system, according to Insilico Medicine.
The two firms will jointly advance the co-development of the R&D program.
Original reporting: Appleton, WI News Feed (HLL/CB) — read the source article.